Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.7.12.1 - dual-specificity kinase and Organism(s) Homo sapiens and UniProt Accession P33981

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
Dual-specificity tyrosine-regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer.
DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth.
DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
Expression of dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma.
Licocoumarone induces BxPC-3 pancreatic adenocarcinoma cell death by inhibiting DYRK1A.
Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer.
Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.
The USP22 promotes the growth of cancer cells through the DYRK1A in pancreatic ductal adenocarcinoma.
Adenocarcinoma of Lung
Amplification and overexpression of the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas.
Frequent DYRK2 gene amplification in micropapillary element of lung adenocarcinoma - an implication in progression in EGFR-mutated lung adenocarcinoma.
Adenocarcinoma, Bronchiolo-Alveolar
Expression of dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma.
Albinism
Ocular findings of albinism in DYRK1A-related intellectual disability syndrome.
Alzheimer Disease
?-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites.
A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition.
A high-performance liquid chromatography assay for Dyrk1a, a Down syndrome-associated kinase.
A novel DYRK1A (Dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
Abnormalities of DYRK1A-Cytoskeleton Complexes in the Blood Cells as Potential Biomarkers of Alzheimer's Disease.
Age-associated motor and visuo-spatial learning phenotype in Dyrk1A heterozygous mutant mice.
Chemical screening identifies the ?-Carboline alkaloid harmine to be synergistically lethal with doxorubicin.
Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer's disease.
Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A.
Design and synthesis of a potent inhibitor of class 1 DYRK kinases as a suppressor of adipogenesis.
Development of novel 2,4-bispyridyl thiophene-based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivatives.
Development of novel amide-derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification.
Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors.
Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1a (DYRK1a) Kinase Inhibitors as Potential Therapeutics.
Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.
Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D.
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
DYRK1A genetic variants are not linked to Alzheimer's disease in a Spanish case-control cohort.
Dyrk1a haploinsufficiency induces diabetes in mice through decreased pancreatic beta cell mass.
DYRK1A inhibition as potential treatment for Alzheimer's disease.
DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective.
Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice.
DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3.
E3 Ligase SCF?TrCP-induced DYRK1A Protein Degradation Is Essential for Cell Cycle Progression in HEK293 Cells.
Further investigation of Paprotrain: Towards the conception of selective and multi-targeted CNS kinase inhibitors.
GSK-3?, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways.
Hologram QSAR Models of a Series of 6-Arylquinazolin-4-Amine Inhibitors of a New Alzheimer's Disease Target: Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase-1A Enzyme.
Identification of a DYRK1A Inhibitor that Induces Degradation of the Target Kinase using Co-chaperone CDC37 fused with Luciferase nanoKAZ.
Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design.
Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice.
Kororamides, Convolutamines, and Indole Derivatives as Possible Tau and Dual-Specificity Kinase Inhibitors for Alzheimer's Disease: A Computational Study.
LPS-Induced Inflammation Abolishes the Effect of DYRK1A on IkB Stability in the Brain of Mice.
Meridianins: marine-derived potent kinase inhibitors.
microRNAs expression correlates with levels of APP, DYRK1A, hyperphosphorylated Tau and BDNF in the hippocampus of a mouse model for Down syndrome during ageing.
Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
Overexpression of miR-26a-5p suppresses Tau phosphorylation and A? accumulation in Alzheimer's disease mice by targeting DYRK1A.
Oxidative and nitrosative modifications of biliverdin reductase-a in the brain of subjects with Alzheimer's disease and amnestic mild cognitive impairment.
Phosphorylation of Munc18-1 by Dyrk1A regulates its interaction with Syntaxin 1 and X11?.
Plasma DYRK1A as a novel risk factor for Alzheimer's disease.
Potent inhibitors of CDK5 derived from roscovitine: synthesis, biological evaluation and molecular modelling.
Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules.
Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?
Regulation of RCAN1 protein activity by Dyrk1A protein-mediated phosphorylation.
REST Regulates DYRK1A Transcription in a Negative Feedback Loop.
Restrained Phosphatidylcholine Synthesis in a Cellular Model of Down's Syndrome is Associated with the Overexpression of Dyrk1A.
Selectivity Profiling and Biological Activity of Novel ?-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors.
Small Molecule Inhibitors of DYRK1A Identified by Computational and Experimental Approaches.
Synthesis and kinase inhibitory activity of novel substituted indigoids.
Synthesis and preliminary in vitro kinase inhibition evaluation of new diversely substituted pyrido[3,4-g]quinazoline derivatives.
Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.
Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease.
The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease.
The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome.
Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I: A MOLECULAR MECHANISM LINKED TO TAU PATHOLOGY IN ALZHEIMER DISEASE.
[b]-Annulated Halogen-Substituted Indoles as Potential DYRK1A Inhibitors.
Amblyopia
Ocular Phenotype Associated with DYRK1A Variants.
Anemia
Crystal Structure of Human Dual-Specificity Tyrosine-Regulated Kinase 3 Reveals New Structural Features and Insights into its Auto-phosphorylation.
DYRK3 dual-specificity kinase attenuates erythropoiesis during anemia.
Anemia, Hemolytic
DYRK3 dual-specificity kinase attenuates erythropoiesis during anemia.
Arthritis, Rheumatoid
Dyrk1A promotes the proliferation, migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis via down-regulating Spry2 and activating the ERK MAPK pathway.
Bone Resorption
Negative-feedback inhibition of NFATc1 by DYRK1A regulates bone homeostasis.
Brain Neoplasms
DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications.
Identification of harmine and ?-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.
Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.
Breast Neoplasms
A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha negative estrogen receptor-beta positive breast cancer cells following estrogen treatment.
Ablation of miR-10b Suppresses Oncogene-Induced Mammary Tumorigenesis and Metastasis and Reactivates Tumor-Suppressive Pathways.
Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2.
Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.
Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer.
Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer.
Dual-specificity tyrosine-regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer.
Dyrk1B overexpression is associated with breast cancer growth and a poor prognosis.
DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail.
DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
Dyrk2-associated EDD-DDB1-VprBP E3 Ligase Inhibits Telomerase by TERT Degradation.
Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer.
Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.
Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis.
Carcinogenesis
Association of chromosome 19 to lung cancer genotypes and phenotypes.
CIRBP Knockdown Attenuates Tumourigenesis and Improves the Chemosensitivity of Pancreatic Cancer via the Downregulation of DYRK1B.
DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291.
DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth.
DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis.
DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis.
Exome sequencing identifies early gastric carcinoma as an early stage of advanced gastric cancer.
Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer.
Impairment of DYRK2 by DNMT1?mediated transcription augments carcinogenesis in human colorectal cancer.
Increased expression of Dyrk1a in HPV16 immortalized keratinocytes enable evasion of apoptosis.
Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor ?2 expression.
MiR-1246: A new link of the p53 family with cancer and Down syndrome.
Targeting dual specificity protein kinase TTK attenuates tumorigenesis of glioblastoma.
The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression.
[Proteomic analysis of proteins related to radiation-induced carcinogenesis]
Carcinoma
A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.
Corrigendum: A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.
DYRK1A is required for maintenance of cancer stemness, contributing to tumorigenic potential in oral/oropharyngeal squamous cell carcinoma.
Effects of marine sponge extracts on mitogen-activated protein kinase (MAPK/ERK(1,2)) activity in SW-13 human adrenal carcinoma cells.
Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.
Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors.
STYK1/NOK correlates with ferroptosis in non-small cell lung carcinoma.
Carcinoma, Ehrlich Tumor
Effect of protein kinase inhibitors on activity of mammalian small heat-shock protein (HSP25) kinase.
Carcinoma, Embryonal
Isolation and characterization of activin receptor from mouse embryonal carcinoma cells. Identification of its serine/threonine/tyrosine protein kinase activity.
Multiple cDNAs encoding the esk kinase predict transmembrane and intracellular enzyme isoforms.
Carcinoma, Hepatocellular
Downregulated DYRK2 expression is associated with poor prognosis and Oxaliplatin resistance in hepatocellular carcinoma.
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 3 Loss Activates Purine Metabolism and Promotes Hepatocellular Carcinoma Progression.
DYRK1 is a co-activator of FKHR (FOXO1a)-dependent glucose-6-phosphatase gene expression.
TROAP switches DYRK1 activity to drive hepatocellular carcinoma progression.
Carcinoma, Non-Small-Cell Lung
DYRK2 expression may be a predictive marker for chemotherapy in non-small cell lung cancer.
Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer.
Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.
STYK1/NOK correlates with ferroptosis in non-small cell lung carcinoma.
STYK1/NOK Promotes Metastasis and Epithelial-Mesenchymal Transition in Non-small Cell Lung Cancer by Suppressing FoxO1 Signaling.
Carcinoma, Squamous Cell
A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.
Corrigendum: A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.
DYRK1A is required for maintenance of cancer stemness, contributing to tumorigenic potential in oral/oropharyngeal squamous cell carcinoma.
Cardiomegaly
Dyrk1a regulates the cardiomyocyte cell cycle via D-cyclin-dependent Rb/E2f-signalling.
Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo.
Hyperhomocysteinemia-induced Dyrk1a downregulation results in cardiomyocyte hypertrophy in rats.
MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling.
Cardiomyopathies
Dyrk1a regulates the cardiomyocyte cell cycle via D-cyclin-dependent Rb/E2f-signalling.
Cardiotoxicity
Chemical screening identifies the ?-Carboline alkaloid harmine to be synergistically lethal with doxorubicin.
Coffin-Lowry Syndrome
High diagnostic yield of clinically unidentifiable syndromic growth disorders by targeted exome sequencing.
Colorectal Neoplasms
Decrease of miR-622 expression suppresses migration and invasion by targeting regulation of DYRK2 in colorectal cancer cells.
Diagnostic relevance of overexpressed serine threonine tyrosine kinase/novel oncogene with kinase domain (STYK1/ NOK) mRNA in colorectal cancer.
Dual-specificity tyrosine-regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer.
Impairment of DYRK2 by DNMT1?mediated transcription augments carcinogenesis in human colorectal cancer.
LncRNA OIP5-AS1 regulates radioresistance by targeting DYRK1A through miR-369-3p in colorectal cancer cells.
Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer.
Congenital Abnormalities
DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective.
Corneal Opacity
Microdeletion of the Down syndrome critical region at 21q22.
Craniofacial Abnormalities
Influence of Prenatal EGCG Treatment and Dyrk1a Dosage Reduction on Craniofacial Features Associated with Down Syndrome.
Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome.
cyclin-dependent kinase deficiency
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
The green tea polyphenol epigallocatechin-3-gallate (EGCG) restores CDKL5-dependent synaptic defects in vitro and in vivo.
Dementia
A Pilot Study Examining Associations between DYRK1A and ?-Synuclein Dementias.
Abnormalities of DYRK1A-Cytoskeleton Complexes in the Blood Cells as Potential Biomarkers of Alzheimer's Disease.
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
microRNA 155 up regulation in the CNS is strongly correlated to Down's syndrome dementia.
The role of DYRK1A in neurodegenerative diseases.
Dengue
Host factor prioritization for pan-viral genetic perturbation screens using random intercept models and network propagation.
Diabetes Mellitus
DYRK1A aggravates ? cell dysfunction and apoptosis by promoting the phosphorylation and degradation of IRS2.
Diabetes Mellitus, Type 1
Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133.
Diabetes Mellitus, Type 2
Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human ?-Cell Proliferation.
Two novel variants in DYRK1B causative of AOMS3: expanding the clinical spectrum.
Down Syndrome
10-Iodo-11H-indolo[3,2-c]quinoline-6-carboxylic Acids Are Selective Inhibitors of DYRK1A.
?-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites.
A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition.
A commentary on: Overexpression of Dyrk1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome.
A comprehensive proteomics-based interaction screen that links DYRK1A to RNF169 and to the DNA damage response.
A high-performance liquid chromatography assay for Dyrk1a, a Down syndrome-associated kinase.
A novel DYRK1A (Dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
A patient with Down syndrome with a de novo derivative chromosome 21.
A repressor complex, AP4 transcription factor and geminin, negatively regulates expression of target genes in nonneuronal cells.
Abnormalities of DYRK1A-Cytoskeleton Complexes in the Blood Cells as Potential Biomarkers of Alzheimer's Disease.
Activation, regulation, and inhibition of DYRK1A.
Activity-Dependent Phosphorylation of Dynamin 1 at Serine 857.
Age-associated motor and visuo-spatial learning phenotype in Dyrk1A heterozygous mutant mice.
Alterations in the phenotype of neocortical pyramidal cells in the Dyrk1A+/- mouse.
Aristolactam BIII, a naturally derived DYRK1A inhibitor, rescues Down syndrome-related phenotypes.
Association of the single nucletide polymorphisms in RUNX1, DYRK1A, and KCNJ15 with blood related traits in pigs.
Attenuation of Notch signalling by the Down-syndrome-associated kinase DYRK1A.
BDNF and DYRK1A Are Variable and Inversely Correlated in Lymphoblastoid Cell Lines from Down Syndrome Patients.
Bioinformatics analysis of biomarkers and transcriptional factor motifs in Down syndrome.
Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome.
Cbs overdosage is necessary and sufficient to induce cognitive phenotypes in mouse models of Down syndrome and interacts genetically with Dyrk1a.
Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene.
Characterization of Caenorhabditis elegans homologs of the Down syndrome candidate gene DYRK1A.
Characterization of the human DYRK1A promoter and its regulation by the transcription factor E2F1.
Clinical manifestations of the deletion of Down syndrome critical region including DYRK1A and KCNJ6.
Cloning and characterization of DYRK1B, a novel member of the DYRK family of protein kinases.
Cloning of a human homolog of the Drosophila minibrain/rat Dyrk gene from "the Down syndrome critical region" of chromosome 21.
Comparative analysis of the DYRK1A-SRSF6-TNNT2 pathway in myocardial tissue from individuals with and without Down syndrome.
Computational & experimental evaluation of the structure/activity relationship of ?-carbolines as DYRK1A inhibitors.
Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A.
Cyclin D1 Again Caught in the Act: Dyrk1a Links G1 and Neurogenesis in Down Syndrome.
DCAF7/WDR68 is required for normal levels of DYRK1A and DYRK1B.
Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A.
Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors.
Disruption of neurogenesis and cortical development in transgenic mice misexpressing Olig2, a gene in the Down syndrome critical region.
Down syndrome and thyroid dysfunction: should nutritional support be the first-line treatment?
Down syndrome phenotype in a boy with a mosaic microduplication of chromosome 21q22.
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1.
Down's syndrome-like cardiac developmental defects in embryos of the transchromosomic Tc1 mouse.
Down's-syndrome-related kinase Dyrk1A modulates the p120-catenin-Kaiso trajectory of the Wnt signaling pathway.
Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1a (DYRK1a) Kinase Inhibitors as Potential Therapeutics.
Dual-specificity Tyrosine Phosphorylation-regulated Kinase 1A (Dyrk1A) Enhances Tau Expression.
Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.
Dual-specificity Tyrosine Phosphorylation-regulated Kinase 1A (Dyrk1A) Modulates Serine/Arginine-rich Protein 55 (SRp55)-promoted Tau Exon 10 Inclusion.
Dual-specificity tyrosine phosphorylation-regulated kinase 1A does not require tyrosine phosphorylation for activity in vitro.
Dual-specificity tyrosine-phosphorylated and regulated kinase 1A (DYRK1A) interacts with the phytanoyl-CoA alpha-hydroxylase associated protein 1 (PAHX-AP1), a brain specific protein.
Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D.
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
DYRK1A (dual-specificity tyrosine-phosphorylated and -regulated kinase 1A): a gene with dosage effect during development and neurogenesis.
DYRK1A and cognition: A lifelong relationship.
DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1.
DYRK1A BAC Transgenic Mouse: A New Model of Thyroid Dysgenesis in Down Syndrome.
DYRK1A binds to an evolutionarily conserved WD40-repeat protein WDR68 and induces its nuclear translocation.
DYRK1A enhances the mitogen-activated protein kinase cascade in PC12 cells by forming a complex with Ras, B-Raf, and MEK1.
Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice.
Dyrk1a haploinsufficiency induces diabetes in mice through decreased pancreatic beta cell mass.
DYRK1A in Down syndrome: an oncogene or tumor suppressor?
Dyrk1A induces pancreatic ? cell mass expansion and improves glucose tolerance.
DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives.
DYRK1A interacts with the REST/NRSF-SWI/SNF chromatin remodelling complex to deregulate gene clusters involved in the neuronal phenotypic traits of Down syndrome.
Dyrk1A is dynamically expressed on subsets of motor neurons and in the neuromuscular junction: possible role in Down syndrome.
DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective.
DYRK1A overexpression decreases plasma lecithin:cholesterol acyltransferase activity and apolipoprotein A-I levels.
DYRK1A overexpression enhances STAT activity and astrogliogenesis in a Down syndrome mouse model.
Dyrk1A overexpression in immortalized hippocampal cells produces the neuropathological features of Down syndrome.
Dyrk1A overexpression inhibits proliferation and induces premature neuronal differentiation of neural progenitor cells.
Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice.
DYRK1A phosphorylates caspase 9 at an inhibitory site and is potently inhibited in human cells by harmine.
Dyrk1A potentiates steroid hormone-induced transcription via the chromatin remodeling factor Arip4.
DYRK1A promotes dopaminergic neuron survival in the developing brain and in a mouse model of Parkinson's disease.
DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down Syndrome.
DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3.
DYRK1A regulates Hap1-Dcaf7/WDR68 binding with implication for delayed growth in Down syndrome.
DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome.
DYRK1A, a novel determinant of the methionine-homocysteine cycle in different mouse models overexpressing this Down-syndrome-associated kinase.
DYRK1A-mediated Cyclin D1 Degradation in Neural Stem Cells Contributes to the Neurogenic Cortical Defects in Down Syndrome.
DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis.
DYRK1A: a potential drug target for multiple Down syndrome neuropathologies.
DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis.
E3 Ligase SCF?TrCP-induced DYRK1A Protein Degradation Is Essential for Cell Cycle Progression in HEK293 Cells.
Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
Epigallocatechin-3-Gallate Plus Omega-3 Restores the Mitochondrial Complex I and F0F1-ATP Synthase Activities in PBMCs of Young Children with Down Syndrome: A Pilot Study of Safety and Efficacy.
Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans.
Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult Down syndrome mice.
Expression of the DYRK1A gene correlates with its 3D positioning in the interphase nucleus of Down syndrome cells.
Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B.
Function and regulation of Dyrk1A: towards understanding Down syndrome.
Gene dosage-dependent association of DYRK1A with the cytoskeleton in the brain and lymphocytes of down syndrome patients.
Generation of improved human cerebral organoids from single copy DYRK1A knockout induced pluripotent stem cells in trisomy 21: hypothetical solutions for neurodevelopmental models and therapeutic alternatives in down syndrome.
Global kinome profiling reveals DYRK1A as critical activator of the human mitochondrial import machinery.
Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A).
Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation.
Identification of a novel actin-dependent signal transducing module allows for the targeted degradation of GLI1.
Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome.
Importance of gene dosage in controlling dendritic arbor formation during development.
Increased Dosage of Dyrk1A Alters Alternative Splicing Factor (ASF)-regulated Alternative Splicing of Tau in Down Syndrome.
Increased dosage of DYRK1A and brain volumetric alterations in a YAC model of partial trisomy 21.
Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.
Increased NR2A expression and prolonged decay of NMDA-induced calcium transient in cerebellum of TgDyrk1A mice, a mouse model of Down syndrome.
Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design.
Influence of Prenatal EGCG Treatment and Dyrk1a Dosage Reduction on Craniofacial Features Associated with Down Syndrome.
Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome.
Inhibition of DYRK1A disrupts neural lineage specification in human pluripotent stem cells.
Intellectual disabilities, neuronal posttranscriptional RNA metabolism, and RNA-binding proteins: three actors for a complex scenario.
Intracellular distribution of differentially phosphorylated dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A).
Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome.
Long-term running alleviates some behavioral and molecular abnormalities in Down syndrome mouse model Ts65Dn.
LPS-Induced Inflammation Abolishes the Effect of DYRK1A on IkB Stability in the Brain of Mice.
Mice Deficient in Cystathionine Beta Synthase Display Increased Dyrk1A and SAHH Activities in Brain.
Microdeletion of the Down syndrome critical region at 21q22.
microRNAs expression correlates with levels of APP, DYRK1A, hyperphosphorylated Tau and BDNF in the hippocampus of a mouse model for Down syndrome during ageing.
Minibrain drives the Dacapo-dependent cell cycle exit of neurons in the Drosophila brain by promoting asense and prospero expression.
MiR-1246: A new link of the p53 family with cancer and Down syndrome.
Molecular Rescue of Dyrk1A Overexpression Alterations in Mice with Fontup® Dietary Supplement: Role of Green Tea Catechins.
Motor phenotypic alterations in TgDyrk1a transgenic mice implicate DYRK1A in Down syndrome motor dysfunction.
Negative-feedback inhibition of NFATc1 by DYRK1A regulates bone homeostasis.
Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome.
New Perspectives of Dyrk1A Role in Neurogenesis and Neuropathologic Features of Down Syndrome.
NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21.
Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome.
Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors.
Nuclear import of the DSCAM-cytoplasmic domain drives signaling capable of inhibiting synapse formation.
Ocular Phenotype Associated with DYRK1A Variants.
Optimization and validation of a DYRK1A TR-FRET assay for high-throughput screening.
Overexpression of Dyrk1A Causes the Defects in Synaptic Vesicle Endocytosis.
Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome.
Overexpression of DYRK1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome.
Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome.
Overexpression of DYRK1A, a Down Syndrome Candidate gene, Impairs Primordial Germ Cells Maintenance and Migration in zebrafish.
Overexpression of Dyrk1A, a Down Syndrome Candidate, Decreases Excitability and Impairs Gamma Oscillations in the Prefrontal Cortex.
Phosphorylation of Munc18-1 by Dyrk1A regulates its interaction with Syntaxin 1 and X11?.
Potent inhibitors of CDK5 derived from roscovitine: synthesis, biological evaluation and molecular modelling.
Prefrontal deficits in a murine model overexpressing the down syndrome candidate gene dyrk1a.
Protein quality control of DYRK family protein kinases by the Hsp90-Cdc37 molecular chaperone.
QSAR and Pharmacophore Study of Dyrk1A Inhibitory Meridianin Analogs as Potential Agents for Treatment of Neurodegenerative Diseases.
Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?
Regulation of RCAN1 protein activity by Dyrk1A protein-mediated phosphorylation.
Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A.
Regulation of the proapoptotic activity of huntingtin interacting protein 1 by Dyrk1 and caspase-3 in hippocampal neuroprogenitor cells.
Rescue of the abnormal skeletal phenotype in Ts65Dn Down syndrome mice using genetic and therapeutic modulation of trisomic Dyrk1a.
REST Regulates DYRK1A Transcription in a Negative Feedback Loop.
Restoring microglial and astroglial homeostasis using DNA immunization in a Down Syndrome mouse model.
Restrained Phosphatidylcholine Synthesis in a Cellular Model of Down's Syndrome is Associated with the Overexpression of Dyrk1A.
Selective DYRK1A Inhibitor for the Treatment of Neurodegenerative Diseases: Alzheimer, Parkinson, Huntington, and Down Syndrome.
Selectivity Profiling and Biological Activity of Novel ?-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors.
Small Molecule Inhibitors of DYRK1A Identified by Computational and Experimental Approaches.
Structural and functional characteristics of Dyrk, a novel subfamily of protein kinases with dual specificity.
Targeting Dyrk1A with AAVshRNA Attenuates Motor Alterations in TgDyrk1A, a Mouse Model of Down Syndrome.
Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits.
Ten new cases further delineate the syndromic intellectual disability phenotype caused by mutations in DYRK1A.
The direct association of Sprouty-related protein with an EVH1 domain (SPRED) 1 or SPRED2 with DYRK1A modifies substrate/kinase interactions.
The Down syndrome candidate dual-specificity tyrosine phosphorylation-regulated kinase 1A phosphorylates the neurodegeneration-related septin 4.
The Down syndrome-related protein kinase DYRK1A phosphorylates p27(Kip1) and Cyclin D1 and induces cell cycle exit and neuronal differentiation.
The DYRK1A gene is a cause of syndromic intellectual disability with severe microcephaly and epilepsy.
The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease.
The MNB/DYRK1A protein kinase: genetic and biochemical properties.
The neurodevelopmental disorder risk gene DYRK1A is required for ciliogenesis and control of brain size in Xenopus embryos.
The nuclear interactome of DYRK1A reveals a functional role in DNA damage repair.
The protein kinase DYRK1A regulates caspase-9-mediated apoptosis during retina development.
The role of DYRK1A in neurodegenerative diseases.
The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome.
Therapeutic Effects of Catechins in Less Common Neurological and Neurodegenerative Disorders.
Transgenic mouse in vivo library of human Down syndrome critical region 1: association between DYRK1A overexpression, brain development abnormalities, and cell cycle protein alteration.
Transient myeloproliferative disorder with partial trisomy 21.
Translating dosage compensation to trisomy 21.
Triple play of DYRK1A kinase in cortical progenitor cells of Trisomy 21.
Triplication of DYRK1A causes retinal structural and functional alterations in Down syndrome.
Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome.
Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I: A MOLECULAR MECHANISM LINKED TO TAU PATHOLOGY IN ALZHEIMER DISEASE.
Truncation of the Down syndrome candidate gene DYRK1A in two unrelated patients with microcephaly.
Two key genes closely implicated with the neuropathological characteristics in Down syndrome: DYRK1A and RCAN1.
Understanding the Multifaceted Role of Human Down Syndrome Kinase DYRK1A.
Vascular defects of DYRK1A knockouts are ameliorated by modulating calcium signaling in zebrafish.
[b]-Annulated Halogen-Substituted Indoles as Potential DYRK1A Inhibitors.
[Minibrain/DYRK1A gene: candidate gene for mental retardation in Down's syndrome?]
[Trisomy 21: fifty years between medicine and science]
dual-specificity kinase deficiency
Arabidopsis YAK1 regulates abscisic acid response and drought resistance.
DYRK1A and cognition: A lifelong relationship.
DYRK1A Is a Regulator of S-Phase Entry in Hepatic Progenitor Cells.
DYRK1a mediates BAFF-induced noncanonical NF-kB activation to promote autoimmunity and B cell leukemogenesis.
DYRK3 dual-specificity kinase attenuates erythropoiesis during anemia.
Epilepsy
Clinical course of epilepsy and white matter abnormality linked to a novel DYRK1A variant.
Clinical manifestations of the deletion of Down syndrome critical region including DYRK1A and KCNJ6.
The DYRK1A gene is a cause of syndromic intellectual disability with severe microcephaly and epilepsy.
Fetal Growth Retardation
Truncation of the Down syndrome candidate gene DYRK1A in two unrelated patients with microcephaly.
Frontotemporal Lobar Degeneration
GSK-3?, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways.
Glioblastoma
An ID2-dependent mechanism for VHL inactivation in cancer.
Dual Specificity Kinase DYRK3 Promotes Aggressiveness of Glioblastoma by Altering Mitochondrial Morphology and Function.
DYRK1A activates NFATC1 to increase glioblastoma migration.
DYRK1A Negatively Regulates CDK5-SOX2 Pathway and Self-Renewal of Glioblastoma Stem Cells.
Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells.
Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.
Inhibition of DYRK1A-EGFR axis by p53-MDM2 cascade mediates the induction of cellular senescence.
Multiple forms of protein kinase from normal human brain and glioblastoma.
NOK mediated mitogenic signaling is altered by P203L and V395I mutations.
Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A.
Targeting dual specificity protein kinase TTK attenuates tumorigenesis of glioblastoma.
Glioma
An ID2-dependent mechanism for VHL inactivation in cancer.
DYRK1A activates NFATC1 to increase glioblastoma migration.
Identification of harmine and ?-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.
Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.
K63-linked ubiquitination of DYRK1A by TRAF2 alleviates Sprouty 2-mediated degradation of EGFR.
Proline Hydroxylation Primes Protein Kinases for Autophosphorylation and Activation.
Protein kinase translocation following beta-adrenergic receptor activation in C6 glioma cells.
Regulation of Glioma Cells Migration by DYRK2.
Hearing Loss, Sensorineural
Novel Causative Variants in DYRK1A, KARS, and KAT6A Associated with Intellectual Disability and Additional Phenotypic Features.
Heart Failure
Involvement of the dual-specificity tyrosine phosphorylation-regulated kinase 1A-alternative splicing factor-calcium/calmodulin-dependent protein kinase II? signaling pathway in myocardial infarction-induced heart failure of rats.
MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling.
Hepatitis
High diagnostic yield of clinically unidentifiable syndromic growth disorders by targeted exome sequencing.
Hepatitis C
Host factor prioritization for pan-viral genetic perturbation screens using random intercept models and network propagation.
HIV Infections
HIV-1-Tat Protein Inhibits SC35-mediated Tau Exon 10 Inclusion through Up-regulation of DYRK1A Kinase.
Hyperhomocysteinemia
Corrective effects of hepatotoxicity by hepatic Dyrk1a gene delivery in mice with intermediate hyperhomocysteinemia.
DYRK1A, a novel determinant of the methionine-homocysteine cycle in different mouse models overexpressing this Down-syndrome-associated kinase.
Dyrk1A, a Serine/Threonine Kinase, is Involved in ERK and Akt Activation in the Brain of Hyperhomocysteinemic Mice.
Effect of hyperhomocysteinemia on the protein kinase DYRK1A in liver of mice.
Hepatocyte-specific Dyrk1a gene transfer rescues plasma apolipoprotein A-I levels and aortic Akt/GSK3 pathways in hyperhomocysteinemic mice.
Homocysteine-lowering gene therapy rescues signaling pathways in brain of mice with intermediate hyperhomocysteinemia.
Hyperhomocysteinemia-induced Dyrk1a downregulation results in cardiomyocyte hypertrophy in rats.
Mice Deficient in Cystathionine Beta Synthase Display Increased Dyrk1A and SAHH Activities in Brain.
Hypertension
Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale.
Hypospadias
Microdeletion of the Down syndrome critical region at 21q22.
Hypothyroidism
Down syndrome and thyroid dysfunction: should nutritional support be the first-line treatment?
Infections
DYRK1 is a co-activator of FKHR (FOXO1a)-dependent glucose-6-phosphatase gene expression.
In vivo and in vitro phosphorylation of DNA-dependent RNA polymerase of Escherichia coli by bacteriophage-T7-induced protein kinase.
Protein kinase of bacteriophage T7. 1. Purification.
The serine/threonine/tyrosine kinase STY46 defends against hordeivirus infection by phosphorylating ?b protein.
Understanding the Multifaceted Role of Human Down Syndrome Kinase DYRK1A.
Inflammatory Breast Neoplasms
A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration.
Influenza, Human
Identification of Host Kinase Genes Required for Influenza Virus Replication and the Regulatory Role of MicroRNAs.
Insulin Resistance
Dual-specificity tyrosine phosphorylation-regulated kinase 1A ameliorates insulin resistance in neurons by up-regulating IRS-1 expression.
Intellectual Disability
A De Novo Mutation in DYRK1A Causes Syndromic Intellectual Disability: A Chinese Case Report.
A high-performance liquid chromatography assay for Dyrk1a, a Down syndrome-associated kinase.
Abnormalities of DYRK1A-Cytoskeleton Complexes in the Blood Cells as Potential Biomarkers of Alzheimer's Disease.
Activation, regulation, and inhibition of DYRK1A.
Activity-Dependent Phosphorylation of Dynamin 1 at Serine 857.
Alterations in the phenotype of neocortical pyramidal cells in the Dyrk1A+/- mouse.
Case report of novel DYRK1A mutations in 2 individuals with syndromic intellectual disability and a review of the literature.
Clinical manifestations of the deletion of Down syndrome critical region including DYRK1A and KCNJ6.
Cloning and characterization of DYRK1B, a novel member of the DYRK family of protein kinases.
Dyrk1 inhibition improves Alzheimer's disease-like pathology.
DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects.
DYRK1A haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies.
DYRK1A interacts with histone acetyl transferase p300 and CBP and localizes to enhancers.
Dyrk1a Mutations Cause Undergrowth of Cortical Pyramidal Neurons via Dysregulated Growth Factor Signaling.
DYRK1A pathogenic variants in two patients with syndromic intellectual disability and a review of the literature.
Dyrk1A phosphorylates alpha-synuclein and enhances intracellular inclusion formation.
Dyrk1A potentiates steroid hormone-induced transcription via the chromatin remodeling factor Arip4.
DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome.
DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis.
Effect of DYRK1A activity inhibition on development of neuronal progenitors isolated from Ts65Dn mice.
Functional characterization of DYRK1A missense variants associated with a syndromic form of intellectual deficiency and autism.
Gene dosage-dependent association of DYRK1A with the cytoskeleton in the brain and lymphocytes of down syndrome patients.
Generation of an induced pluripotent stem cell line from a patient with global development delay carrying DYRK1A mutation (c.1730T>A) and a gene correction isogenic iPSC line.
Integrative approach to interpret DYRK1A variants, leading to a frequent neurodevelopmental disorder.
Intragenic deletion in DYRK1A leads to mental retardation and primary microcephaly.
Negative-feedback inhibition of NFATc1 by DYRK1A regulates bone homeostasis.
Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome.
Novel Causative Variants in DYRK1A, KARS, and KAT6A Associated with Intellectual Disability and Additional Phenotypic Features.
Ocular findings of albinism in DYRK1A-related intellectual disability syndrome.
Ocular Phenotype Associated with DYRK1A Variants.
Overexpression of Dyrk1A Causes the Defects in Synaptic Vesicle Endocytosis.
Overexpression of DYRK1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome.
QSAR and Pharmacophore Study of Dyrk1A Inhibitory Meridianin Analogs as Potential Agents for Treatment of Neurodegenerative Diseases.
Regulation of the proapoptotic activity of huntingtin interacting protein 1 by Dyrk1 and caspase-3 in hippocampal neuroprogenitor cells.
Restoring microglial and astroglial homeostasis using DNA immunization in a Down Syndrome mouse model.
Restrained Phosphatidylcholine Synthesis in a Cellular Model of Down's Syndrome is Associated with the Overexpression of Dyrk1A.
Structural and functional characteristics of Dyrk, a novel subfamily of protein kinases with dual specificity.
Ten new cases further delineate the syndromic intellectual disability phenotype caused by mutations in DYRK1A.
The DYRK1A gene is a cause of syndromic intellectual disability with severe microcephaly and epilepsy.
The neurodevelopmental disorder risk gene DYRK1A is required for ciliogenesis and control of brain size in Xenopus embryos.
The role of DYRK1A in neurodegenerative diseases.
Unraveling the genetic etiology of adult antisocial behavior: a genome-wide association study.
[Identification of a de novo interstitial 21q22.12q22.13 deletion in a patient with intellectual disability].
[Minibrain/DYRK1A gene: candidate gene for mental retardation in Down's syndrome?]
Kidney Failure, Chronic
Corrective effects of hepatotoxicity by hepatic Dyrk1a gene delivery in mice with intermediate hyperhomocysteinemia.
Language Development Disorders
Generation of an induced pluripotent stem cell line from a patient with global development delay carrying DYRK1A mutation (c.1730T>A) and a gene correction isogenic iPSC line.
Learning Disabilities
Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome.
Leukemia
DYRK1A phoshorylates histone H3 to differentially regulate the binding of HP1 isoforms and antagonize HP1-mediated transcriptional repression.
DYRK2 controls a key regulatory network in chronic myeloid leukemia stem cells.
Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.
KLF4 Represses DYRK2 Inhibition of Self-renewal and Survival Through c-Myc and p53 in Leukemia Stem/Progenitor Cells.
Nuclear trafficking of pro-apoptotic kinases in response to DNA damage.
Overexpression of Serine Threonine Tyrosine Kinase 1/Novel Oncogene with Kinase Domain mRNA in Patients with Acute Leukemia.
The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome.
Leukemia, Lymphoid
The murine PKR tumor suppressor gene is rearranged in a lymphocytic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DYRK2 controls a key regulatory network in chronic myeloid leukemia stem cells.
Leukemia, Myeloid
Overexpression of chromatin remodeling and tyrosine kinase genes in iAMP21-positive acute lymphoblastic leukemia.
Lipoma
Identification of novel HMGA2 fusion sequences in lipoma: Evidence that deletion of let-7 miRNA consensus binding site 1 in the HMGA2 3' UTR is not critical for HMGA2 transcriptional upregulation.
Liposarcoma
Targeting DYRK1B suppresses the proliferation and migration of liposarcoma cells.
Liver Diseases
Corrective effects of hepatotoxicity by hepatic Dyrk1a gene delivery in mice with intermediate hyperhomocysteinemia.
Liver Neoplasms
Forced expression of DYRK2 exerts anti-tumor effects via apoptotic induction in liver cancer.
Utility of the dual-specificity protein kinase TTK as a therapeutic target for intrahepatic spread of liver cancer.
Lung Neoplasms
DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291.
DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors.
DYRK2 expression may be a predictive marker for chemotherapy in non-small cell lung cancer.
Emerging roles of DYRK2 in cancer.
Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer.
Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.
STYK1/NOK Promotes Metastasis and Epithelial-Mesenchymal Transition in Non-small Cell Lung Cancer by Suppressing FoxO1 Signaling.
Lymphatic Metastasis
[Expression and clinical significance of Dyrk1b in the specimens and cells of cervical lesions].
Lymphoma
Altered regulation of cyclic AMP-dependent protein kinase in a mouse lymphoma cell line.
Subunit interaction in cyclic AMP-dependent protein kinase of mutant lymphoma cells.
Lymphoma, B-Cell
Hepato-protective effect of rutin via IL-6/STAT3 pathway in CCl4-induced hepatotoxicity in rats.
Lymphoma, Non-Hodgkin
Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.
Memory Disorders
Cbs overdosage is necessary and sufficient to induce cognitive phenotypes in mouse models of Down syndrome and interacts genetically with Dyrk1a.
Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A.
DCAF7/WDR68 is required for normal levels of DYRK1A and DYRK1B.
Dual-specificity tyrosine phosphorylation-regulated kinase 1A does not require tyrosine phosphorylation for activity in vitro.
DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects.
Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice.
Putative therapeutic agents for the learning and memory deficits of people with Down syndrome.
QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors.
Metabolic Syndrome
A form of the metabolic syndrome associated with mutations in DYRK1B.
Design and synthesis of a potent inhibitor of class 1 DYRK kinases as a suppressor of adipogenesis.
DYRK1B mutations associated with metabolic syndrome impair the chaperone-dependent maturation of the kinase domain.
DYRK1B variant linked to autosomal dominant metabolic syndrome.
Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.
Minibrain-related kinase/dual-specificity tyrosine-regulated kinase 1B implication in stem/cancer stem cells biology.
Mutational analysis of two residues in the DYRK homology box of the protein kinase DYRK1A.
Study of DYRK1B gene expression and its association with metabolic syndrome in a small cohort of Egyptians.
The metabolic syndrome and DYRK1B.
Microcephaly
Case report of novel DYRK1A mutations in 2 individuals with syndromic intellectual disability and a review of the literature.
DYRK1A haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies.
DYRK1A interacts with histone acetyl transferase p300 and CBP and localizes to enhancers.
Dyrk1a Mutations Cause Undergrowth of Cortical Pyramidal Neurons via Dysregulated Growth Factor Signaling.
DYRK1A mutations in two unrelated patients.
DYRK1A pathogenic variants in two patients with syndromic intellectual disability and a review of the literature.
DYRK1A promotes dopaminergic neuron survival in the developing brain and in a mouse model of Parkinson's disease.
DYRK1A-haploinsufficiency in mice causes autistic-like features and febrile seizures.
DYRK1A: A master regulatory protein controlling brain growth.
Generation of an induced pluripotent stem cell line from a patient with global development delay carrying DYRK1A mutation (c.1730T>A) and a gene correction isogenic iPSC line.
Generation of improved human cerebral organoids from single copy DYRK1A knockout induced pluripotent stem cells in trisomy 21: hypothetical solutions for neurodevelopmental models and therapeutic alternatives in down syndrome.
Global kinome profiling reveals DYRK1A as critical activator of the human mitochondrial import machinery.
Inhibition of DYRK1A disrupts neural lineage specification in human pluripotent stem cells.
Intragenic deletion in DYRK1A leads to mental retardation and primary microcephaly.
Investigation of copy number variations on chromosome 21 detected by comparative genomic hybridization (CGH) microarray in patients with congenital anomalies.
Microdeletion of the Down syndrome critical region at 21q22.
Novel Causative Variants in DYRK1A, KARS, and KAT6A Associated with Intellectual Disability and Additional Phenotypic Features.
Precision Revisited: Targeting Microcephaly Kinases in Brain Tumors.
Targeted next-generation sequencing in the diagnosis of neurodevelopmental disorders.
Ten new cases further delineate the syndromic intellectual disability phenotype caused by mutations in DYRK1A.
The DYRK1A gene is a cause of syndromic intellectual disability with severe microcephaly and epilepsy.
The neurodevelopmental disorder risk gene DYRK1A is required for ciliogenesis and control of brain size in Xenopus embryos.
Truncation of the Down syndrome candidate gene DYRK1A in two unrelated patients with microcephaly.
Neoplasm Metastasis
Dual-specificity tyrosine-regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer.
DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail.
Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B.
STYK1/NOK Promotes Metastasis and Epithelial-Mesenchymal Transition in Non-small Cell Lung Cancer by Suppressing FoxO1 Signaling.
[Expression and clinical significance of Dyrk1b in the specimens and cells of cervical lesions].
Neoplasms
A cell-based screening method for specifically detecting kinase activity.
A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.
A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3? to phosphorylate cyclin D1 at Thr(286), not Thr(288).
A wake-up call to quiescent cancer cells - potential use of DYRK1B inhibitors in cancer therapy.
Aberrant expression of STYK1 and E-cadherin confer a poor prognosis for pancreatic cancer patients.
Ablation of miR-10b Suppresses Oncogene-Induced Mammary Tumorigenesis and Metastasis and Reactivates Tumor-Suppressive Pathways.
Amplification and overexpression of the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas.
An ID2-dependent mechanism for VHL inactivation in cancer.
Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2.
Assessment of Genetic Aspects of Non-alcoholic Fatty Liver and Premature Cardiovascular Events.
Characterization of protein tyrosine kinase activity in murine Leydig tumor cells.
CIRBP Knockdown Attenuates Tumourigenesis and Improves the Chemosensitivity of Pancreatic Cancer via the Downregulation of DYRK1B.
Comparison of Cancer Cell Survival Triggered by Microtubule Damage after Turning Dyrk1B Kinase On and Off.
Crystal structure of the catalytic domain of the mitotic checkpoint kinase Mps1 in complex with SP600125.
Curcumin as an Alternative Epigenetic Modulator: Mechanism of Action and Potential Effects.
Data supporting a pilot high-throughput screen of a drug library for identification of DYRK1A inhibitors and high-content imaging analysis of identified harmine analogs.
Decrease of miR-622 expression suppresses migration and invasion by targeting regulation of DYRK2 in colorectal cancer cells.
Design and synthesis of a potent inhibitor of class 1 DYRK kinases as a suppressor of adipogenesis.
Diagnostic relevance of overexpressed serine threonine tyrosine kinase/novel oncogene with kinase domain (STYK1/ NOK) mRNA in colorectal cancer.
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1.
Downregulated DYRK2 expression is associated with poor prognosis and Oxaliplatin resistance in hepatocellular carcinoma.
Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer.
Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer.
Downregulation of GLUT3 impairs STYK1/NOK-mediated metabolic reprogramming and proliferation in NIH-3T3 cells.
Dual Specificity Kinase DYRK3 Promotes Aggressiveness of Glioblastoma by Altering Mitochondrial Morphology and Function.
Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1a (DYRK1a) Kinase Inhibitors as Potential Therapeutics.
Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.
Dual-specificity tyrosine-regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer.
DYRK1A in Down syndrome: an oncogene or tumor suppressor?
DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications.
DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291.
DYRK1A is required for maintenance of cancer stemness, contributing to tumorigenic potential in oral/oropharyngeal squamous cell carcinoma.
DYRK1A kinase inhibitors with emphasis on cancer.
DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth.
DYRK1A Negatively Regulates CDK5-SOX2 Pathway and Self-Renewal of Glioblastoma Stem Cells.
Dyrk1A promotes the proliferation, migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis via down-regulating Spry2 and activating the ERK MAPK pathway.
DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors.
DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis.
DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis.
DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance.
Dyrk1B overexpression is associated with breast cancer growth and a poor prognosis.
DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail.
DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells.
DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
Effect of protein kinase inhibitors on activity of mammalian small heat-shock protein (HSP25) kinase.
Emerging roles of DYRK2 in cancer.
Engagement of DYRK2 in proper control for cell division.
Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.
Exploring the link between germline and somatic genetic alterations in breast carcinogenesis.
Forced expression of DYRK2 exerts anti-tumor effects via apoptotic induction in liver cancer.
Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B.
Frequent DYRK2 gene amplification in micropapillary element of lung adenocarcinoma - an implication in progression in EGFR-mutated lung adenocarcinoma.
Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia.
Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells.
Harmine, a dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor induces caspase-mediated apoptosis in neuroblastoma.
How to design potent and selective DYRK1B inhibitors? Molecular modeling study.
Human biliverdin reductase suppresses Goodpasture antigen-binding protein (GPBP) kinase activity: the reductase regulates tumor necrosis factor-alpha-NF-kappaB-dependent GPBP expression.
Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.
Identification of harmine and ?-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.
Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer.
Impairment of DYRK2 by DNMT1?mediated transcription augments carcinogenesis in human colorectal cancer.
Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression.
Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.
Inhibition of DYRK1A-EGFR axis by p53-MDM2 cascade mediates the induction of cellular senescence.
Isoform selectivity of harmine-conjugated 1,2,3-triazoles against human monoamine oxidase.
K63-linked ubiquitination of DYRK1A by TRAF2 alleviates Sprouty 2-mediated degradation of EGFR.
Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer.
Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor ?2 expression.
Minibrain and Wings apart control organ growth and tissue patterning through down-regulation of Capicua.
Minibrain-related kinase/dual-specificity tyrosine-regulated kinase 1B implication in stem/cancer stem cells biology.
Molecular basis underlying resistance to Mps1/TTK inhibitors.
Molecular targets for tumour progression in gastrointestinal stromal tumours.
Multi-layered proteomic analyses decode compositional and functional effects of cancer mutations on kinase complexes.
Multiple functions of DYRK2 in cancer and tissue development.
New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
Novel trisubstituted harmine derivatives with original in vitro anticancer activity.
Optimization and validation of a DYRK1A TR-FRET assay for high-throughput screening.
Phosphorylation-dependent regulation of the NOTCH1 intracellular domain by dual-specificity tyrosine-regulated kinase 2.
Proline Hydroxylation Primes Protein Kinases for Autophosphorylation and Activation.
Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors.
Regulating protein breakdown through proteasome phosphorylation.
Regulation of Glioma Cells Migration by DYRK2.
Role of dual specificity tyrosine-phosphorylation-regulated kinase 1B (Dyrk1B) in S-phase entry of HPV E7 expressing cells from quiescence.
Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.
Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis.
Small Molecule Inhibitors of DYRK1A Identified by Computational and Experimental Approaches.
Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors.
STYK1 promotes autophagy through enhancing the assembly of autophagy-specific class III phosphatidylinositol 3-kinase complex I.
STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
Synthesis and biological activities of aminopyrimidyl-indoles structurally related to meridianins.
Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A.
Synthesis, Resolution, and Biological Evaluation of Atropisomeric (aR)- and (aS)-16-Methyllamellarins N: Unique Effects of the Axial Chirality on the Selectivity of Protein Kinases Inhibition.
The Human Novel Gene LNC-HC Inhibits Hepatocellular Carcinoma Cell Proliferation by Sequestering hsa-miR-183-5p.
The nuclear interactome of DYRK1A reveals a functional role in DNA damage repair.
The stress-responsive kinase DYRK2 activates heat shock factor 1 promoting resistance to proteotoxic stress.
The Tumor Suppressor NKX3.1 Is Targeted for Degradation by DYRK1B Kinase.
The USP22 promotes the growth of cancer cells through the DYRK1A in pancreatic ductal adenocarcinoma.
TROAP switches DYRK1 activity to drive hepatocellular carcinoma progression.
Tumor suppressor DYRK1A effects on proliferation and chemoresistance of AML cells by downregulating c-Myc.
Tumour necrosis factor alpha enhances the expression of hydroxyl lyase, cytoplasmic antiproteinase-2 and a dual specificity kinase TTK in human chondrocyte-like cells.
Understanding the Multifaceted Role of Human Down Syndrome Kinase DYRK1A.
Up-regulation of Dyrk1b promote astrocyte activation following lipopolysaccharide-induced neuroinflammation.
Updating dual-specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2): molecular basis, functions and role in diseases.
Vascular defects of DYRK1A knockouts are ameliorated by modulating calcium signaling in zebrafish.
[Expression and clinical significance of Dyrk1b in the specimens and cells of cervical lesions].
Nervous System Diseases
Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human ?-Cell Proliferation.
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic ?-cell proliferation activity.
Neuroblastoma
DYRK3 contributes to differentiation and hypoxic control in neuroblastoma.
Epigallocatechin-3-gallate inhibits the growth of three-dimensional in vitro models of neuroblastoma cell SH-SY5Y.
Functional Interactions between BM88/Cend1, Ran-binding protein M and Dyrk1B kinase affect cyclin D1 levels and cell cycle progression/exit in mouse neuroblastoma cells.
Harmine, a dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor induces caspase-mediated apoptosis in neuroblastoma.
Iron-induced oxidative stress activates AKT and ERK1/2 and decreases Dyrk1B and PRMT1 in neuroblastoma SH-SY5Y cells.
Participation of type II protein kinase A in the retinoic acid-induced growth inhibition of SH-SY5Y human neuroblastoma cells.
Phosphorylation of endogenous proteins by adenosine 3':5'-monophosphate-dependent protein kinase in mouse neuroblastoma cells.
Subcellular distribution of cyclin-dependent kinase-like 5 (CDKL5) is regulated through phosphorylation by dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A).
The Down syndrome-related protein kinase DYRK1A phosphorylates p27(Kip1) and Cyclin D1 and induces cell cycle exit and neuronal differentiation.
The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease.
Vascular defects of DYRK1A knockouts are ameliorated by modulating calcium signaling in zebrafish.
Neurodegenerative Diseases
A high-performance liquid chromatography assay for Dyrk1a, a Down syndrome-associated kinase.
Activation, regulation, and inhibition of DYRK1A.
Computational & experimental evaluation of the structure/activity relationship of ?-carbolines as DYRK1A inhibitors.
Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors.
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
DYRK1A and cognition: A lifelong relationship.
DYRK1A inhibition as potential treatment for Alzheimer's disease.
DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis.
Further investigation of Paprotrain: Towards the conception of selective and multi-targeted CNS kinase inhibitors.
Homocysteine-lowering gene therapy rescues signaling pathways in brain of mice with intermediate hyperhomocysteinemia.
Library-based discovery of DYRK1A/CLK1 inhibitors from natural product extracts.
Molecular Rescue of DYRK1A Overexpression in Cystathionine Beta Synthase-Deficient Mouse Brain by Enriched Environment Combined with Voluntary Exercise.
New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
Oxidative and nitrosative modifications of biliverdin reductase-a in the brain of subjects with Alzheimer's disease and amnestic mild cognitive impairment.
QSAR and Pharmacophore Study of Dyrk1A Inhibitory Meridianin Analogs as Potential Agents for Treatment of Neurodegenerative Diseases.
Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?
Selective DYRK1A Inhibitor for the Treatment of Neurodegenerative Diseases: Alzheimer, Parkinson, Huntington, and Down Syndrome.
Selectivity Profiling and Biological Activity of Novel ?-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors.
Synthesis, Resolution, and Biological Evaluation of Atropisomeric (aR)- and (aS)-16-Methyllamellarins N: Unique Effects of the Axial Chirality on the Selectivity of Protein Kinases Inhibition.
The Down syndrome candidate dual-specificity tyrosine phosphorylation-regulated kinase 1A phosphorylates the neurodegeneration-related septin 4.
The role of DYRK1A in neurodegenerative diseases.
[b]-Annulated Halogen-Substituted Indoles as Potential DYRK1A Inhibitors.
Neuroinflammatory Diseases
Dyrk2 involved in regulating LPS-induced neuronal apoptosis.
Dyrk2 mediated the release of proinflammatory cytokines in LPS-induced BV2 cells.
Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease.
The novel DYRK1A inhibitor KVN93 regulates cognitive function, amyloid-beta pathology, and neuroinflammation.
Up-regulation of Dyrk1b promote astrocyte activation following lipopolysaccharide-induced neuroinflammation.
Obesity
Design and synthesis of a potent inhibitor of class 1 DYRK kinases as a suppressor of adipogenesis.
Phosphorylation and Inactivation of Glycogen Synthase Kinase 3? (GSK3?) by Dual-specificity Tyrosine Phosphorylation-regulated Kinase 1A (Dyrk1A).
Oligodendroglioma
Minibrain and Wings apart control organ growth and tissue patterning through down-regulation of Capicua.
Optic Atrophy
High diagnostic yield of clinically unidentifiable syndromic growth disorders by targeted exome sequencing.
Optic Nerve Hypoplasia
Ocular Phenotype Associated with DYRK1A Variants.
Osteoarthritis, Knee
Lorecivivint, a Novel Intraarticular CDC-Like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial.
Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment.
Ovarian Neoplasms
DYRK1B blocks canonical and promotes non-canonical Hedgehog signaling through activation of the mTOR/AKT pathway.
DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
Pancreatic Neoplasms
CIRBP Knockdown Attenuates Tumourigenesis and Improves the Chemosensitivity of Pancreatic Cancer via the Downregulation of DYRK1B.
Key role of dual specificity kinase TTK in proliferation and survival of pancreatic cancer cells.
Licocoumarone induces BxPC-3 pancreatic adenocarcinoma cell death by inhibiting DYRK1A.
Parkinson Disease
A Pilot Study Examining Associations between DYRK1A and ?-Synuclein Dementias.
Association of DYRK1A polymorphisms with sporadic Parkinson's disease in Chinese Han population.
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
DYRK1A promotes dopaminergic neuron survival in the developing brain and in a mouse model of Parkinson's disease.
GSK-3?, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways.
Understanding the Multifaceted Role of Human Down Syndrome Kinase DYRK1A.
Pick Disease of the Brain
Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Pituitary Neoplasms
Identification of Seven Cell Cycle-Related Genes with Unfavorable Prognosis and Construction of their TF-miRNA-mRNA regulatory network in Breast Cancer.
Plasmacytoma
Resolution and general properties of different types of ribosomal protein kinases in mouse plasmocytoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Doubling up on function: dual-specificity tyrosine-regulated kinase 1A (DYRK1A) in B cell acute lymphoblastic leukemia.
DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3.
Prostatic Neoplasms
The Tumor Suppressor NKX3.1 Is Targeted for Degradation by DYRK1B Kinase.
Pseudolymphoma
Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.
Psoriasis
MicroRNA-215-5p inhibits the proliferation of keratinocytes and alleviates psoriasis-like inflammation by negatively regulating DYRK1A and its downstream signalling pathways.
Refractive Errors
Ocular Phenotype Associated with DYRK1A Variants.
Refsum Disease
Dual-specificity tyrosine-phosphorylated and regulated kinase 1A (DYRK1A) interacts with the phytanoyl-CoA alpha-hydroxylase associated protein 1 (PAHX-AP1), a brain specific protein.
Retinoblastoma
Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells.
Rett Syndrome
Intellectual disabilities, neuronal posttranscriptional RNA metabolism, and RNA-binding proteins: three actors for a complex scenario.
Sarcoma
Viral src gene products are related to the catalytic chain of mammalian cAMP-dependent protein kinase.
Sarcoma, Avian
Cytosolic malic dehydrogenase activity is associated with a putative substrate for the transforming gene product of Rous sarcoma virus.
Protein kinase and its regulatory effect on reverse transcriptase activity of Rous sarcoma virus.
Scoliosis
Investigation of copy number variations on chromosome 21 detected by comparative genomic hybridization (CGH) microarray in patients with congenital anomalies.
Seizures
DYRK1A mutations in two unrelated patients.
Excitation/inhibition balance and learning are modified by Dyrk1a gene dosage.
Generation of an induced pluripotent stem cell line from a patient with global development delay carrying DYRK1A mutation (c.1730T>A) and a gene correction isogenic iPSC line.
The DYRK1A gene is a cause of syndromic intellectual disability with severe microcephaly and epilepsy.
Seizures, Febrile
DYRK1A-haploinsufficiency in mice causes autistic-like features and febrile seizures.
Sepsis
Constructing a 10-core genes panel for diagnosis of pediatric sepsis.
Severe Acute Respiratory Syndrome
Host factor prioritization for pan-viral genetic perturbation screens using random intercept models and network propagation.
Squamous Cell Carcinoma of Head and Neck
A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.
Corrigendum: A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.
Status Epilepticus
miRNA-187-3p-mediated regulation of the KCNK10/TREK-2 potassium channel in a rat epilepsy model.
Strabismus
Ocular Phenotype Associated with DYRK1A Variants.
Stroke
Genome-wide meta-analysis identifies 3 novel loci associated with stroke.
LIM kinase inhibitor T56-LIMKi protects mouse brain from photothrombotic stroke.
Tauopathies
Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
Dual-specificity Tyrosine Phosphorylation-regulated Kinase 1A (Dyrk1A) Enhances Tau Expression.
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Thyroid Dysgenesis
DYRK1A BAC Transgenic Mouse: A New Model of Thyroid Dysgenesis in Down Syndrome.
Triple Negative Breast Neoplasms
Emerging roles of DYRK2 in cancer.
Urinary Bladder Neoplasms
Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) as a novel marker in T1 high-grade and T2 bladder cancer patients receiving neoadjuvant chemotherapy.
Uterine Cervical Neoplasms
[Expression and clinical significance of Dyrk1b in the specimens and cells of cervical lesions].
Uterine Cervicitis
[Expression and clinical significance of Dyrk1b in the specimens and cells of cervical lesions].
Vascular Diseases
Vascular defects of DYRK1A knockouts are ameliorated by modulating calcium signaling in zebrafish.